2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Epoxide Hydrolase

Epoxide Hydrolase

Epoxide Hydrolase

Related Products

PDF 0.26 MB

Epoxide hydrolases (EH) present in all living organisms. The mammalian soluble epoxide hydrolase (sEH) is a 120 kDa dimer of two identical 62.5 kDa monomers arranged in an anti-parallel fashion. It is mostly expressed in the liver, kidneys, brain, endothelium, and at lesser levels in other tissues. Inflammation and pain are major components of many disease states. Mammalian sEH inhibition reduces blood pressure, inflammation and pain. The anti-inflammatory activities of sEH inhibitors occur in part through the NF-κB mediated down-regulation of COX2 transcription, resulting in lower production of pro-inflammatory prostaglandins such as PGE2 and PGD2.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-135653A
    (Rac)-EC5026
    		Inhibitor 98.25%
    (Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB).
    (Rac)-EC5026
  • HY-148000
    sEH inhibitor-6
    		Inhibitor
    sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.5 nM.
    sEH inhibitor-6
  • HY-155029
    sEH inhibitor-16
    		Inhibitor
    sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitors with an IC50 of 2 nM. sEH inhibitor-16 reduces the inflammatory damage in Cerulein (HY-A0190)-induced acute pancreatitis (AP) in mice and can be used for inflammation/immunology research.
    sEH inhibitor-16
  • HY-W013989R
    1,3-Dicyclohexylurea (Standard)
    		Inhibitor
    1,3-Dicyclohexylurea (Standard) is the analytical standard of 1,3-Dicyclohexylurea. This product is intended for research and analytical applications. 1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
    1,3-Dicyclohexylurea (Standard)
  • HY-151616
    sEH inhibitor-10
    		Inhibitor
    sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases.
    sEH inhibitor-10
  • HY-144738
    Dual FAAH/sEH-IN-1
    		Inhibitor
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
    Dual FAAH/sEH-IN-1
  • HY-121549
    S-NEPC
    S-NEPC (4-Nitrophenyl-2S,3S-epoxy-3 phenylpropyl carbonate) is a colorimetric substrate used to measure epoxide hydrolase activity.
    S-NEPC
  • HY-W013989
    1,3-Dicyclohexylurea
    		Inhibitor
    1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
    1,3-Dicyclohexylurea
  • HY-146704
    COX-2/sEH-IN-1
    		Inhibitor
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
    COX-2/sEH-IN-1
  • HY-N12528
    10,11-EDT
    10,11-EDT, a soluble epoxide hydrolase (sEH) substrate, is a metabolic product of adrenic acid. 10,11-EDT is an endothelium-derived hyperpolarizing factor with strong vasorelaxant effects.
    10,11-EDT
  • HY-156329
    sEH/FLAP-IN-1
    		Inhibitor
    sEH/FLAP-IN-1 (Compound 46A) is a sEH/FLAP inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC50: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC50: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases.
    sEH/FLAP-IN-1
  • HY-146643
    sEH inhibitor-3
    		Inhibitor
    sEH inhibitor-3 (compound 35) is a potent and orally active soluble epoxide hydrolase (sEH) inhibitor with a Ki of 0.75 nM for human sEH.
    sEH inhibitor-3
  • HY-148573
    sEH inhibitor-14
    		Inhibitor
    sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
    sEH inhibitor-14
  • HY-120494
    sEH inhibitor-1
    		Inhibitor 99.62%
    sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of sEH (soluble epoxide hydrolase) with IC50s of 0.4 and 5.3 nM in human and murine, respectively.
    sEH inhibitor-1
  • HY-147732
    sEH inhibitor-4
    Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.
    sEH inhibitor-4
  • HY-B2117R
    Valpromide (Standard)
    		Inhibitor
    Valpromide (Standard) is the analytical standard of Valpromide. This product is intended for research and analytical applications. Valpromide is an amide derivative of valproic acid and inhibits human epoxide hydrolase.
    Valpromide (Standard)
  • HY-151619
    sEH inhibitor-12
    		Inhibitor
    sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC50 value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC50 value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation.
    sEH inhibitor-12
  • HY-163207
    sEH/HDAC6-IN-1
    		Inhibitor
    sEH/HDAC6-IN-1 (compound M9) is a selective, orally active dual inhibitor for sEH and HDAC6, with IC50s of 2 nM, 0.72 nM and 5 nM, for human sEH, murine sEH and HDAC6, respectively. sEH/HDAC6-IN-1 reveals analgesic and anti-inflammatory effects.
    sEH/HDAC6-IN-1
  • HY-160676
    sEH-IN-1
    		Inhibitor
    sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on.
    sEH-IN-1
  • HY-151621
    sEH inhibitor-13
    		Inhibitor
    sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.4 μM.
    sEH inhibitor-13
Cat. No. Product Name / Synonyms Application Reactivity